Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Ximenia caffra fruit contains quercetin-rutinoside and condensed tannins that inhibit collagenase and elastase enzymes while suppressing NF-κB inflammatory pathways. The fruit demonstrates potent antioxidant activity with DPPH IC50 values of 5 μg/mL and total phenolic content of 261.87 mg GAE/g.
Reported Benefits (Provisional)
Origin & History
Ximenia caffra, also known as Sour Plum, is indigenous to Southern Africa, particularly Zimbabwe, Mozambique, and South Africa. This resilient fruit thrives in dry woodlands and sandy soils, valued for its traditional uses and unique nutritional profile.
Research Narrative (Provisional)
Research highlights Ximenia caffra's rich fatty acid profile, particularly ximenynic acid, and its antioxidant compounds, supporting its traditional use for skin repair and anti-inflammatory effects. Studies also indicate immune-supportive properties, warranting further investigation.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Fatty Acids: Ximenynic acid, oleic acid, stearic acid, palmitic acid (in seed oil) for skin nourishment and anti-inflammatory effects. - Vitamins: Vitamin C (immune support), Tocopherols (Vitamin E, antioxidant). - Polyphenols: Gallic acid, catechins, quercetin for antioxidant and anti-inflammatory benefits. - Phytosterols: Support cellular health and cholesterol regulation.
Reported Mechanism (Provisional)
Ximenia caffra's bioactive compounds, particularly quercetin-rutinoside (9.08 mg/g) and condensed tannins, inhibit skin-degrading enzymes including collagenase, elastase, hyaluronidase, and tyrosinase at levels comparable to reference drugs. The fruit suppresses inflammatory pathways by downregulating NF-κB signaling, reducing IL-6, iNOS, and TNF-α mRNA expression. Additionally, it enhances cellular stress resistance through DAF-16 nuclear localization (up to 10-fold increase) and HSP 16.2 downregulation to 86.4%.
Clinical Narrative (Provisional)
Current evidence for Ximenia caffra is limited to in vitro studies and animal models using C. elegans, with no randomized clinical trials or human studies reported. Laboratory studies demonstrate antioxidant capacity of 1.46 mmol Trolox/g and antiproliferative effects with IC50 values of 239.0 ± 44.5 μg/mL in RAW cells. The fruit extract shows antimicrobial activity against Pseudomonas aeruginosa biofilms and contains 23 identified secondary metabolites with total polyphenol content of approximately 19.45 mg/g. While traditional uses are well-documented, controlled human trials are needed to validate therapeutic efficacy and establish clinical dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.